KRAS: From undruggable to a druggable Cancer Target
D Uprety, AA Adjei - Cancer treatment reviews, 2020 - Elsevier
RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …
Clinical actionability of molecular targets in endometrial cancer
ME Urick, DW Bell - Nature Reviews Cancer, 2019 - nature.com
Abstract Endometrial cancer accounts for~ 76,000 deaths among women each year
worldwide. Disease mortality and the increasing number of new diagnoses make …
worldwide. Disease mortality and the increasing number of new diagnoses make …
Classification of endometrial carcinoma: more than two types
R Murali, RA Soslow, B Weigelt - The Lancet Oncology, 2014 - thelancet.com
Endometrial cancer is the most common gynaecological malignancy in Europe and North
America. Traditional classification of endometrial carcinoma is based either on clinical and …
America. Traditional classification of endometrial carcinoma is based either on clinical and …
Endometrial cancer
F Amant, P Moerman, P Neven, D Timmerman… - The Lancet, 2005 - thelancet.com
Each year, endometrial cancer develops in about 142 000 women worldwide, and an
estimated 42 000 women die from this cancer. The typical age-incidence curve for …
estimated 42 000 women die from this cancer. The typical age-incidence curve for …
Molecular genetics of endometrial carcinoma
DW Bell, LH Ellenson - Annual Review of Pathology …, 2019 - annualreviews.org
Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United
States. Endometrioid endometrial carcinomas constitute approximately 85% of newly …
States. Endometrioid endometrial carcinomas constitute approximately 85% of newly …
[HTML][HTML] Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and …
A Yemelyanova, R Vang, M Kshirsagar, D Lu… - Modern pathology, 2011 - Elsevier
Immunohistochemical staining for p53 is used as a surrogate for mutational analysis in the
diagnostic workup of carcinomas of multiple sites including ovarian cancers. Strong and …
diagnostic workup of carcinomas of multiple sites including ovarian cancers. Strong and …
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
LWT Cheung, BT Hennessy, J Li, S Yu, AP Myers… - Cancer discovery, 2011 - AACR
We demonstrate that phosphatidylinositol 3-kinase (PI3K) pathway aberrations occur in>
80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K …
80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K …
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer
BM Slomovitz, RL Coleman - Clinical Cancer Research, 2012 - AACR
Endometrial cancer is the most common gynecologic malignancy in the United States.
Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important …
Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important …
Factors associated with Type I and Type II endometrial cancer
Objective We investigated risk factors for Type II (n= 176) vs. Type I (n= 1,576) endometrial
cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008. Methods …
cancer (EC) in cases treated at Magee-Womens Hospital between 1996 and 2008. Methods …
Molecular and pathologic aspects of endometrial carcinogenesis
JL Hecht, GL Mutter - Journal of clinical oncology, 2006 - ascopubs.org
Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases
projected in the United States for 2006. Two different clinicopathologic subtypes are …
projected in the United States for 2006. Two different clinicopathologic subtypes are …